Labospace

Labospace

Milan, Italy· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2015 and headquartered in Milan, Italy, Labospace operates as a service provider in the Diagnostics and Digital Health sectors. Its core business is offering high-throughput, multiplexed biomarker assay services using technologies such as Luminex, alongside distributing IVD reagents and educational tools. The company is ISO-certified, targets a diverse client base from pharma to academia, and emphasizes flexible, cost-effective laboratory solutions.

DiagnosticsDigital Health

Technology Platform

Utilizes high-throughput platforms including Luminex/multiplex assays, Next-Generation Sequencing (NGS), Flow Cytometry (FACS), and Immunohistochemistry (IHC) to provide customized biomarker assay and analytical services.

Opportunities

Growing demand for outsourced, high-throughput biomarker analysis from pharma and biotech companies driving personalized medicine.
Expansion of educational product sales (MiniOne Systems) into life science curricula.
Strategic location in Milan provides access to a dense European network of academic and industrial clients.

Risk Factors

High dependency on third-party technology platforms (e.g., Luminex) and potential supplier issues.
Intense competition in the contract research services market from larger global CROs and local labs.
Revenue vulnerability due to project-based, cyclical client work in the biopharma sector.

Competitive Landscape

Labospace competes in the fragmented contract research and lab services market, facing competition from large global CROs (e.g., LabCorp, IQVIA), specialized central labs, and numerous small local service providers. Its differentiation lies in platform flexibility, customization, and a focus on the Italian/European market. In educational products, it competes with other suppliers of classroom molecular biology equipment.